1. Generics Bulletin
  2. >>Products
  3. >>Generics

Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?

Third Quarter Numbers Follow Sandoz’ View Of ‘Challenging Environment’

 
• By Dean Rudge

Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.

Bumpy road
Are US generics players in for a bumpy road? • Source: Alamy

Teva has followed its rival Sandoz in reporting a soft quarter of US generics sales, adding to debate that recent stability in the US generics sector amid the coronavirus pandemic – stability that Teva itself has repeatedly underlined – is at risk.

The Israeli firm reported North America generics sales, albeit including a small Canadian biosimilars presence, that fell by 7% to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products